UAE Shifts Focus from Weight Scale to Holistic Health in Obesity Fight

The traditional approach to discussing obesity, which focused solely on the number on a scale, is evolving in the UAE. Recent data from the Ministry of Health and Prevention’s National Health and Nutrition Survey 2024-2025 reveals that 22.4 per cent of adults in the UAE are living with obesity. The survey also highlighted significant prevalence of related health issues, with over half of adults experiencing high cholesterol, approximately a quarter having high blood pressure, and one in eight having raised blood glucose levels. These conditions often coexist, underscoring obesity's recognition as a serious, chronic disease closely linked to Type 2 diabetes and heart disease. Consequently, the conversation is increasingly centered on overall cardiometabolic health.

Venkat Kalyan, general manager of Novo Gulf, emphasizes the company's commitment to "lasting health," aiming for well-being that endures. He notes the substantial growth in data and knowledge regarding the science of obesity, stressing the urgency to disseminate this information widely. Kalyan also addresses the societal perception of obesity, noting that it is frequently misconstrued as a lack of willpower, a stigma that deters individuals from seeking necessary medical help. "It’s a chronic disease, and it deserves the same medical care as any other," he asserts, challenging the notion that it is merely a matter of personal discipline.

The link between excess weight and cardiovascular strain is a critical area of recent research. Novo's GLP-1 medicine, which modulates appetite by mimicking a natural hormone, has been utilized since 2017, initially for Type 2 diabetes and later for weight management. In the UAE, this injectable medication is also approved to mitigate the risk of major cardiovascular events, such as heart attack and stroke, in adults with existing heart disease and who are overweight or obese. "We’re seeing benefits beyond weight loss," Kalyan states, indicating a paradigm shift in how the condition is managed, with a greater emphasis on long-term health outcomes rather than just weight reduction.

The UAE has prioritized obesity and chronic diseases as national health and economic concerns. Its regulatory bodies are known for their swift approval of new medical treatments while maintaining stringent safety standards. In June, the Emirates Drug Establishment approved the tablet form of the GLP-1 for weight management, positioning the UAE as the first country after the US to do so. This offers an additional treatment option for suitable patients. Novo Gulf, a company with a long history dating back to 1923, is expanding its presence in the region, with plans for a new regional distribution center in the UAE. "The UAE has set out a clear ambition on chronic disease, and we want to be part of delivering it," Kalyan adds, highlighting a long-term commitment.

Despite advancements in medical treatments, Kalyan reiterates that lifestyle factors such as diet and physical activity remain fundamental to obesity management. He stresses the importance of medical guidance from a doctor who considers the individual's overall health. NovoCare, an educational program by Novo Gulf, offers digital tools, a call center, and patient educators to support individuals in understanding and managing their condition. "Professional medical guidance is essential, and patient safety is extremely important," Kalyan concludes. "The most important step anyone can take is an honest conversation with their doctor, and the earlier, the better."